A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
Status:
Recruiting
Trial end date:
2024-05-28
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled study in patients with dilated
cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA). The
study will further evaluate a dose level of study drug (ARRY-371797) that has shown
preliminary efficacy and safety in this patient population. After the primary analysis has
been performed, eligible patients may receive open-label treatment with ARRY-371797.